{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:20:22Z","timestamp":1793812822030,"version":"4.6.1"},"reference-count":291,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jncc.2025.04.004","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T15:16:31Z","timestamp":1748099791000},"page":"42-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Furong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-781X","authenticated-orcid":false,"given":"Jeffrey W.","family":"Shevach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2636-7145","authenticated-orcid":false,"given":"Qianben","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jncc.2025.04.004_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0003","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.jncc.2025.04.004_bib0004","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jncc.2025.04.004_bib0005","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0008","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0009","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","article-title":"Accelerating precision medicine in metastatic prostate cancer","volume":"1","author":"Mateo","year":"2020","journal-title":"Nat Cancer"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0011","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1242\/dev.200394","article-title":"Prostate organogenesis","volume":"149","author":"Pletcher","year":"2022","journal-title":"Development"},{"issue":"2 Pt 2","key":"10.1016\/j.jncc.2025.04.004_bib0013","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-5347(02)80307-X","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"167","author":"Huggins","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0014","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1210\/endo-114-2-659","article-title":"Biphasic effects of estrogen on gonadotropin-releasing hormone-induced luteinizing hormone release in monolayer cultures of rat and monkey pituitary cells","volume":"114","author":"Frawley","year":"1984","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11255-018-1854-5","article-title":"Estrogen therapy in patients with prostate cancer: a contemporary systematic review","volume":"50","author":"Reis","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0016","first-page":"6889","article-title":"Legends in urology","volume":"20","author":"Schally","year":"2013","journal-title":"Can J Urol"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0017","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/jm701249f","article-title":"Non-peptide gonadotropin-releasing hormone receptor antagonists","volume":"51","author":"Betz","year":"2008","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0015-0282(16)43461-8","article-title":"Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone","volume":"30","author":"Sandow","year":"1978","journal-title":"Fertil Steril"},{"issue":"10398","key":"10.1016\/j.jncc.2025.04.004_bib0282","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0283","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"18","key":"10.1016\/j.jncc.2025.04.004_bib0284","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2004-861547","article-title":"Adrenal androgens and intracrinology","volume":"22","author":"Labrie","year":"2004","journal-title":"Semin Reprod Med"},{"issue":"21","key":"10.1016\/j.jncc.2025.04.004_bib0020","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-18-1187","article-title":"Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: A post hoc analysis of the PR.7 trial","volume":"24","author":"Toren","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0021","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","article-title":"Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo","volume":"20","author":"Germain","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0022","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrd3516","article-title":"Abiraterone acetate","volume":"10","author":"Logothetis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0023","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0960-0760(03)00070-0","article-title":"Effects of novel 17alpha-hydroxylase\/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo","volume":"84","author":"Haidar","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"21","key":"10.1016\/j.jncc.2025.04.004_bib0024","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"5-6","key":"10.1016\/j.jncc.2025.04.004_bib0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","article-title":"Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase)","volume":"50","author":"Barrie","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/joe.0.0450531","article-title":"A soluble androgen receptor in the cytoplasm of rat prostate","volume":"45","author":"Mainwaring","year":"1969","journal-title":"J Endocrinol"},{"issue":"15","key":"10.1016\/j.jncc.2025.04.004_bib0027","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","article-title":"Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival","volume":"115","author":"Akaza","year":"2009","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0028","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"issue":"32","key":"10.1016\/j.jncc.2025.04.004_bib0029","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5928","key":"10.1016\/j.jncc.2025.04.004_bib0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0031","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0033","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with Darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jncc.2025.04.004_bib0034","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"5531","key":"10.1016\/j.jncc.2025.04.004_bib0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154943","article-title":"Targeting mutations in cancer","volume":"132","author":"Waarts","year":"2022","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0037","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0038","first-page":"314","article-title":"Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer","volume":"57","author":"Koivisto","year":"1997","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0039","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0040","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.jncc.2025.04.004_bib0042","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Waltering","year":"2009","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0043","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0045","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"7406","key":"10.1016\/j.jncc.2025.04.004_bib0046","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.jncc.2025.04.004_bib0047","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0048","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"issue":"7637","key":"10.1016\/j.jncc.2025.04.004_bib0049","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0050","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"issue":"312","key":"10.1016\/j.jncc.2025.04.004_bib0051","doi-asserted-by":"crossref","first-page":"312re310","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0052","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0053","article-title":"Plasma androgen receptor copy number status at emergence of metastatic castration-resistant prostate cancer: A pooled multicohort analysis","volume":"3","author":"Jayaram","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0054","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.04.004_bib0056","article-title":"Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer","volume":"3:","author":"Torquato","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0057","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0060","doi-asserted-by":"crossref","first-page":"zcad045","DOI":"10.1093\/narcan\/zcad045","article-title":"Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer","volume":"5","author":"Zivanovic","year":"2023","journal-title":"NAR Cancer"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0061","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/humu.22046","article-title":"The androgen receptor gene mutations database: 2012 update","volume":"33","author":"Gottlieb","year":"2012","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0062","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<559::AID-PATH471>3.0.CO;2-Y","article-title":"Androgen receptor gene mutations in hormone-refractory prostate cancer","volume":"189","author":"Wall\u00e9n","year":"1999","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0063","first-page":"944","article-title":"Androgen receptor mutations in prostate cancer","volume":"60","author":"Marcelli","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0064","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41391-022-00491-z","article-title":"Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids","volume":"26","author":"Snaterse","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0066","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1634\/theoncologist.2019-0115","article-title":"Comprehensive analysis of AR alterations in circulating tumor DNA from patients with advanced prostate cancer","volume":"25","author":"Ledet","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0067","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1074\/jbc.M206172200","article-title":"Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment","volume":"278","author":"Thin","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0068","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/mend.11.4.9906","article-title":"Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells","volume":"11","author":"Tan","year":"1997","journal-title":"Mol Endocrinol"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0069","first-page":"1541","article-title":"Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone","volume":"7","author":"Culig","year":"1993","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0071","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0072","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1039\/C5MB00499C","article-title":"Interaction mechanism exploration of R-bicalutamide\/S-1 with WT\/W741L AR using molecular dynamics simulations","volume":"11","author":"Liu","year":"2015","journal-title":"Mol Biosyst"},{"issue":"42","key":"10.1016\/j.jncc.2025.04.004_bib0073","doi-asserted-by":"crossref","first-page":"30910","DOI":"10.1074\/jbc.M705524200","article-title":"Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12","volume":"282","author":"Cantin","year":"2007","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0074","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajur.2020.01.001","article-title":"Regulation of androgen receptor variants in prostate cancer","volume":"7","author":"Zhu","year":"2020","journal-title":"Asian J Urol"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0076","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0077","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0078","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0079","doi-asserted-by":"crossref","first-page":"T87","DOI":"10.1530\/ERC-13-0470","article-title":"Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer","volume":"21","author":"Ware","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.jncc.2025.04.004_bib0081","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0082","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","article-title":"JMJD6 Is a druggable oxygenase that regulates AR-V7 expression in prostate cancer","volume":"81","author":"Paschalis","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0083","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.jncc.2025.04.004_bib0084","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 Represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.jncc.2025.04.004_bib0087","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.08.029","article-title":"ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer","volume":"72","author":"Cai","year":"2018","journal-title":"Mol Cell"},{"issue":"13","key":"10.1016\/j.jncc.2025.04.004_bib0089","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"39","key":"10.1016\/j.jncc.2025.04.004_bib0090","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0091","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7921","key":"10.1016\/j.jncc.2025.04.004_bib0092","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0093","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jncc.2025.04.004_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.720727","article-title":"Circulating cell-free DNA-based detection of tumor suppressor gene copy number loss and its clinical implication in metastatic prostate cancer","volume":"11","author":"Dong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0096","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1593\/neo.08428","article-title":"Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer","volume":"10","author":"Liu","year":"2008","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0097","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.04.004_bib0098","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0099","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0101","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"issue":"6596","key":"10.1016\/j.jncc.2025.04.004_bib0102","doi-asserted-by":"crossref","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molcel.2007.05.041","article-title":"A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth","volume":"27","author":"Wang","year":"2007","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0104","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41588-022-01045-8","article-title":"HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer","volume":"54","author":"Lu","year":"2022","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0105","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1093\/nar\/gkt1382","article-title":"Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer","volume":"42","author":"Wu","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"33","key":"10.1016\/j.jncc.2025.04.004_bib0106","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1038\/onc.2015.496","article-title":"FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression","volume":"35","author":"Zhao","year":"2016","journal-title":"Oncogene"},{"issue":"51","key":"10.1016\/j.jncc.2025.04.004_bib0107","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.1421415111","article-title":"GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex","volume":"111","author":"He","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7504","key":"10.1016\/j.jncc.2025.04.004_bib0108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0109","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"issue":"7893","key":"10.1016\/j.jncc.2025.04.004_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.03.001","article-title":"CHD1 Loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"issue":"45","key":"10.1016\/j.jncc.2025.04.004_bib0112","doi-asserted-by":"crossref","first-page":"42852","DOI":"10.1074\/jbc.M206061200","article-title":"A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression","volume":"277","author":"Wang","year":"2002","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0113","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/emboj.2011.154","article-title":"Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth","volume":"30","author":"Chen","year":"2011","journal-title":"Embo j"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0114","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/2159-8290.CD-19-0189","article-title":"CDK7 Inhibition suppresses castration-resistant prostate cancer through MED1 inactivation","volume":"9","author":"Rasool","year":"2019","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0115","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1093\/nar\/gkac246","article-title":"Phosphorylated MED1 links transcription recycling and cancer growth","volume":"50","author":"Chen","year":"2022","journal-title":"Nucleic Acids Research"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0116","doi-asserted-by":"crossref","first-page":"502","DOI":"10.15252\/embj.201490306","article-title":"Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer","volume":"34","author":"Chen","year":"2015","journal-title":"Embo j"},{"issue":"19","key":"10.1016\/j.jncc.2025.04.004_bib0117","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1093\/nar\/gkz790","article-title":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0118","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","article-title":"ZNF397 Deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0119","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41588-024-01893-6","article-title":"NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis","volume":"56","author":"Parolia","year":"2024","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0120","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","article-title":"FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer","volume":"180","author":"Gerhardt","year":"2012","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0121","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2559.2011.03796.x","article-title":"High-level expression of forkhead-box protein A1 in metastatic prostate cancer","volume":"58","author":"Jain","year":"2011","journal-title":"Histopathology"},{"issue":"21","key":"10.1016\/j.jncc.2025.04.004_bib0122","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1158\/0008-5472.CAN-11-1882","article-title":"Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.04.004_bib0123","article-title":"SCORT\u2013Cas13d nanotherapy precisely targets the \u2018undruggable\u2019 Transcription factor HoxB13 in metastatic prostate cancer In vivo","author":"Cui","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0124","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI122367","article-title":"Targeting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression","volume":"129","author":"Song","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115312","article-title":"CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer","volume":"44","author":"Xiang","year":"2025","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0126","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajur.2019.11.001","article-title":"Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer","volume":"7","author":"Wen","year":"2020","journal-title":"Asian J Urol"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0127","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/apm.12030","article-title":"Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers","volume":"121","author":"Kim","year":"2013","journal-title":"Apmis"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","article-title":"Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants","volume":"6","author":"An","year":"2014","journal-title":"Cell Rep"},{"issue":"19","key":"10.1016\/j.jncc.2025.04.004_bib0130","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","article-title":"Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer","volume":"74","author":"Geng","year":"2014","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0131","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0132","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ccr.2013.02.016","article-title":"The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity","volume":"23","author":"Qi","year":"2013","journal-title":"Cancer Cell"},{"issue":"31","key":"10.1016\/j.jncc.2025.04.004_bib0133","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403331121","article-title":"USP11 promotes prostate cancer progression by up-regulating AR and c-myc activity","volume":"121","author":"Pornour","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0134","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s42003-023-05709-x","article-title":"A carboxy-terminal ubiquitylation site regulates androgen receptor activity","volume":"7","author":"Arai","year":"2024","journal-title":"Commun Biol"},{"issue":"21","key":"10.1016\/j.jncc.2025.04.004_bib0135","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","article-title":"The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer","volume":"10","author":"Nishiyama","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0136","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jncc.2025.04.004_bib0137","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cbi.2014.12.012","article-title":"The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer","volume":"234","author":"Tamae","year":"2015","journal-title":"Chem Biol Interact"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0138","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/JU.0000000000000699","article-title":"Extragonadal steroids contribute significantly to androgen receptor activity and development of castration resistance in recurrent prostate cancer after primary therapy","volume":"203","author":"Pouliot","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0139","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0140","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.annonc.2020.04.473","article-title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype","volume":"31","author":"Lu","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0141","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","article-title":"HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","volume":"31","author":"Khalaf","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0142","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/35094009","article-title":"The development of androgen-independent prostate cancer","volume":"1","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0143","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","article-title":"Mechanisms underlying the development of androgen-independent prostate cancer","volume":"12","author":"Pienta","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0144","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jncc.2025.04.004_bib0145","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20183","article-title":"Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer","volume":"6","author":"Li","year":"2017","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0146","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0147","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrurol.2015.254","article-title":"Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy","volume":"13","author":"Narayanan","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0148","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0149","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000501640","article-title":"Recognition and treatment of adrenal insufficiency secondary to abiraterone: A case report and literature review","volume":"97","author":"Baloch","year":"2019","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0150","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/pr.58.4.9","article-title":"International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors","volume":"58","author":"Lu","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0151","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0092-8674(89)90051-2","article-title":"Determinants of target gene specificity for steroid\/thyroid hormone receptors","volume":"57","author":"Umesono","year":"1989","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0152","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","article-title":"Loss and revival of androgen receptor signaling in advanced prostate cancer","volume":"40","author":"Formaggio","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0153","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0154","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0156","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Mod Pathol"},{"issue":"6320","key":"10.1016\/j.jncc.2025.04.004_bib0157","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"issue":"6320","key":"10.1016\/j.jncc.2025.04.004_bib0158","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0159","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from Human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0160","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0161","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.10.009","article-title":"Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0162","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0163","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0164","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jncc.2025.04.004_bib0166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2020.04.013","article-title":"Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer","volume":"134","author":"Zhou","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0167","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS290","article-title":"A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Petrylak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2021.39.6_suppl.108","article-title":"A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"39","author":"Zhou","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0286","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e16542","article-title":"An open label phase 1\/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Rathkopf","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0225","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2016.34.15_suppl.5017","article-title":"Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study)","volume":"34","author":"Bono","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0287","doi-asserted-by":"crossref","first-page":"TPS178","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS178","article-title":"A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novometastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281)","volume":"39","author":"Fizazi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0288","doi-asserted-by":"crossref","first-page":"TPS5123","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123","volume":"42","author":"Chi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0289","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0275","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-Human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0267","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"issue":"5_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0290","first-page":"TPS287","article-title":"PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-na\u00efve patients with metastatic castration-resistant prostate cancer (mCRPC): the phase 3, randomized MEVPRO-2 trial","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0291","doi-asserted-by":"crossref","first-page":"TPS288","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS288","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: the phase 3, randomized MEVPRO-1 study","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jncc.2025.04.004_bib0168","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","article-title":"Targeting androgen receptor activation Function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0169","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0170","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0171","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"Invest New Drugs"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0172","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101115","article-title":"Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease","volume":"14","author":"Maylin","year":"2021","journal-title":"Transl Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0173","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1878-0261.12770","article-title":"Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer","volume":"14","author":"Hirayama","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0174","article-title":"N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/nar\/gkac1158","article-title":"Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0176","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41589-022-01151-y","article-title":"Targeting androgen receptor phase separation to overcome antiandrogen resistance","volume":"18","author":"Xie","year":"2022","journal-title":"Nat Chem Biol"},{"issue":"14","key":"10.1016\/j.jncc.2025.04.004_bib0177","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1073\/pnas.0401123101","article-title":"Structural basis of androgen receptor binding to selective androgen response elements","volume":"101","author":"Shaffer","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.jncc.2025.04.004_bib0178","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1073\/pnas.0807282106","article-title":"Non-competitive androgen receptor inhibition in vitro and in vivo","volume":"106","author":"Jones","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0179","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1021\/acsomega.8b03205","article-title":"Mechanistic investigation of the androgen receptor DNA-binding domain inhibitor pyrvinium","volume":"4","author":"Pal","year":"2019","journal-title":"ACS Omega"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0180","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1535-7163.MCT-17-0259","article-title":"Bypassing drug resistance mechanisms of prostate cancer with small molecules that target androgen receptor-chromatin interactions","volume":"16","author":"Dalal","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jncc.2025.04.004_bib0181","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2018.08.016","article-title":"Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer","volume":"437","author":"Dalal","year":"2018","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0182","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-pharmtox-030624-110238","article-title":"PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate cancer","volume":"65","author":"Wang","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0183","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0184","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42003-018-0105-8","article-title":"Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance","volume":"1","author":"Salami","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0186","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 Ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front Chem"},{"issue":"6_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0187","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jncc.2025.04.004_bib0188","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2020.38.15_suppl.3500","article-title":"First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI)","volume":"38","author":"Petrylak","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"10.1016\/j.jncc.2025.04.004_bib0189","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-ND03","article-title":"Abstract ND03: discovery of ARV-766, an androgen receptor degrading PROTAC\u00ae for the treatment of men with metastatic castration resistant prostate cancer","volume":"83","author":"Snyder","year":"2023","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.jncc.2025.04.004_bib0191","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1021\/acs.jmedchem.3c01264","article-title":"Discovery of ARD-1676 as a highly potent and orally efficacious AR PROTAC degrader with a broad activity against AR mutants for the treatment of AR + Human prostate cancer","volume":"66","author":"Xiang","year":"2023","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0192","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.jncc.2025.04.004_bib0193","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0194","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-17-0976","article-title":"Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer","volume":"77","author":"Ponnusamy","year":"2017","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0195","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0196","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41585-022-00686-y","article-title":"The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications","volume":"20","author":"Kumar","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0197","first-page":"1809","article-title":"LNCaP model of human prostatic carcinoma","volume":"43","author":"Horoszewicz","year":"1983","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0198","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/pros.2990090305","article-title":"Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP","volume":"9","author":"Berns","year":"1986","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0199","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1038\/s41467-024-52032-y","article-title":"Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells","volume":"15","author":"Safi","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jncc.2025.04.004_bib0200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0039-128X(96)00086-4","article-title":"Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells","volume":"61","author":"Dai","year":"1996","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.jncc.2025.04.004_bib0201","first-page":"1566","article-title":"Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation","volume":"54","author":"Kokontis","year":"1994","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1677\/ERC-08-0205","article-title":"DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer","volume":"16","author":"D'Antonio","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"41","key":"10.1016\/j.jncc.2025.04.004_bib0203","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1073\/pnas.0603057103","article-title":"Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells","volume":"103","author":"Litvinov","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0204","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2022.01.039","article-title":"Exploiting the tumor-suppressive activity of the androgen receptor by CDK4\/6 inhibition in castration-resistant prostate cancer","volume":"30","author":"Han","year":"2022","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.jncc.2025.04.004_bib0205","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-20-3607","article-title":"Supraphysiologic testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer","volume":"81","author":"Kumar","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0206","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0207","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53734-z","article-title":"Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0208","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2009.02.022","article-title":"A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer","volume":"56","author":"Szmulewitz","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0209","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.eururo.2009.03.073","article-title":"Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer","volume":"56","author":"Morris","year":"2009","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.jncc.2025.04.004_bib0210","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/pros.23209","article-title":"Bipolar androgen therapy for men with androgen ablation na\u00efve prostate cancer: results from the phase II BATMAN study","volume":"76","author":"Schweizer","year":"2016","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0211","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.eururo.2020.06.042","article-title":"A multicohort open-label Phase II trial of Bipolar androgen Therapy in men with metastatic castration-resistant prostate cancer (RESTORE): A comparison of post-abiraterone versus post-enzalutamide cohorts","volume":"79","author":"Markowski","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0212","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2020.11.043","article-title":"Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy","volume":"144","author":"Sena","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0213","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study","volume":"19","author":"Teply","year":"2018","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jncc.2025.04.004_bib0214","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162396","article-title":"Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC","volume":"132","author":"Sena","year":"2022","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0215","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0216","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clgc.2021.08.001","article-title":"Molecular and clinical characterization of patients with metastatic castration resistant prostate cancer achieving deep responses to bipolar androgen therapy","volume":"20","author":"Markowski","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"269","key":"10.1016\/j.jncc.2025.04.004_bib0217","doi-asserted-by":"crossref","first-page":"269ra262","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0218","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0219","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0221","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0222","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0223","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0224","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II study evaluating Akt Blockade with Ipatasertib, in combination with Abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6330","key":"10.1016\/j.jncc.2025.04.004_bib0226","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jncc.2025.04.004_bib0227","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0228","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0229","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0230","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-018-4848-x","article-title":"Genomic analysis of DNA repair genes and androgen signaling in prostate cancer","volume":"18","author":"Jividen","year":"2018","journal-title":"BMC Cancer"},{"issue":"7015","key":"10.1016\/j.jncc.2025.04.004_bib0231","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massagu\u00e9","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0232","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with Ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0233","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0234","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/cancers9120172","article-title":"PRIMA-1 and PRIMA-1(Met) (APR-246): from mutant\/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies","volume":"9","author":"Perdrix","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"29","key":"10.1016\/j.jncc.2025.04.004_bib0235","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"issue":"484","key":"10.1016\/j.jncc.2025.04.004_bib0236","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0237","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0238","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"2 Pt 2","key":"10.1016\/j.jncc.2025.04.004_bib0239","first-page":"E99","article-title":"Sipuleucel-T (Provenge\u00ae) for castration-resistant prostate cancer","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0240","article-title":"Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0241","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0242","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jncc.2025.04.004_bib0243","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0244","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus Docetaxel versus Docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jncc.2025.04.004_bib0246","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2721","article-title":"1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): randomized double-blind phase III KEYNOTE-641 study","volume":"34","author":"Graff","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jncc.2025.04.004_bib0247","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Nava Rodrigues","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0248","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/aja202283","article-title":"Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer","volume":"25","author":"Zhu","year":"2023","journal-title":"Asian J Androl"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0249","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol"},{"issue":"537","key":"10.1016\/j.jncc.2025.04.004_bib0250","doi-asserted-by":"crossref","first-page":"eaaz3577","DOI":"10.1126\/scitranslmed.aaz3577","article-title":"Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer","volume":"12","author":"Subudhi","year":"2020","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.jncc.2025.04.004_bib0251","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0252","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.jncc.2025.04.004_bib0253","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","article-title":"Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.jncc.2025.04.004_bib0254","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jncc.2025.04.004_bib0255","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0256","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cellimm.2015.02.004","article-title":"Suppressive effects of androgens on the immune system","volume":"294","author":"Trigunaite","year":"2015","journal-title":"Cell Immunol"},{"issue":"2","key":"10.1016\/j.jncc.2025.04.004_bib0257","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers9020013","article-title":"Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy","volume":"9","author":"Kalina","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0258","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1158\/1078-0432.CCR-13-1026","article-title":"Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model","volume":"19","author":"Ardiani","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0259","doi-asserted-by":"crossref","first-page":"T297","DOI":"10.1530\/ERC-17-0145","article-title":"Androgen deprivation and immunotherapy for the treatment of prostate cancer","volume":"24","author":"Gamat","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"27","key":"10.1016\/j.jncc.2025.04.004_bib0260","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1073\/pnas.1402468111","article-title":"Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation","volume":"111","author":"Kissick","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jncc.2025.04.004_bib0261","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"issue":"7915","key":"10.1016\/j.jncc.2025.04.004_bib0262","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0263","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.04.004_bib0264","first-page":"9","article-title":"Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches","volume":"8","author":"Khorasanchi","year":"2025","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0265","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.jncc.2025.04.004_bib0266","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2025.04.004_bib0268","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/cncr.34190","article-title":"Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer","volume":"128","author":"Mendes","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0269","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0270","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2016.69.7748","article-title":"Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer","volume":"35","author":"Kantoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jncc.2025.04.004_bib0271","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2025.04.004_bib0272","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jncc.2025.04.004_bib0273","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: A game changer in cancer treatment","author":"Alm\u00e5sbak","year":"2016","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0274","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jncc.2025.04.004_bib0276","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100761","article-title":"Cross-resistance and drug sequence in prostate cancer","volume":"56","author":"Buck","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"7782","key":"10.1016\/j.jncc.2025.04.004_bib0277","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jncc.2025.04.004_bib0278","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jncc.2025.04.004_bib0279","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0280","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR-Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.jncc.2025.04.004_bib0281","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41388-024-03239-2","article-title":"Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer","volume":"44","author":"Huang","year":"2025","journal-title":"Oncogene"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:31:17Z","timestamp":1775100677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266700542500047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":291,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266700542500047X"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.04.004","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}